Recombinant collagen & gelatin

01Overview and value chain

Markers: [EC: Novel Food Regulation (EU 2015/2283) & Circular Economy Action Plan | OECD: Bio-based advanced materials & industrial biotechnology | Regulator: FDA (US), EMA (EU), NMPA (China)]

Recombinant collagen and gelatin replace acid- or alkali-extracted animal hide and bone collagen with precision-fermentation-derived or plant-farmed protein, eliminating prion-contamination risk, allergenicity and batch-to-batch variability while meeting halal, kosher and vegan requirements. Geltor’s PrimaColl, a biodesigned collagen polypeptide engineered to mimic avian Type 21 collagen, became the first biodesigned collagen cleared for both food and beauty applications in October 2025 — a milestone that opened the door to collagen use in food, beverages and dietary supplements without any animal-derived material. HTL Biotechnology produces recombinant human Collagen III (rhCOLIII) with 100% sequence identity to native human collagen, manufactured by fermentation from non-animal sources for medical-grade applications including subcutaneous use. CollPlant’s rhCollagen platform produces Type I recombinant human collagen through molecular farming in genetically engineered tobacco plants, and its Collink.3D bioink — based on methacrylated rhCollagen — supplies 3D bioprinting applications; the company launched its ready-to-print BioFlex bioink in February 2026 and reported Q1 2026 financial results in May 2026. Jellatech, backed in part by CULT Food Science’s venture arm, develops animal-free gelatin and collagen and was included in a Bezos Earth Fund-backed research center at North Carolina State University. Jellagen (UK), producing jellyfish-derived Collagen Type Zero, formed a strategic partnership with US-based Royal Biologics in early 2026 to commercialize the material for the North American regenerative-medicine market, covering wound care and tissue-engineering applications. In China, Sichuan University’s National Engineering Research Center for Biomaterials published a 2026 regulatory-science paper on pre-market immunological evaluation strategy for recombinant collagen medical devices, addressing the growing domestic pipeline of recombinant-collagen-based medical device registrations.

The key directions of recombinant collagen and gelatin are:

1. Precision-fermentation collagen for food and supplements: engineered yeast strains secreting collagen polypeptides cleared for direct use in food, beverages and dietary supplements.
2. Medical-grade recombinant human collagen: fermentation-derived collagen with exact human sequence identity for subcutaneous, wound-care and implantable medical device applications.
3. Plant molecular farming for collagen: genetically engineered tobacco or other plants expressing recombinant human collagen, avoiding both animal sourcing and microbial fermentation infrastructure.
4. Animal-free gelatin for confectionery and pharma: cell-free or yeast-based gelatin production targeting gelatin’s traditional uses in candy, soft capsules and pharmaceutical excipients.

Sectoral value chain

[Genetic assembly of collagen genes + P4H] ──> [Upstream fermentation (yeast/bacteria) or plant molecular farming] ──> [Downstream purification (limited proteolysis)]
                                                                                                                                       │
                                                                                                                       (Precision drying & sterilization)
                                                                                                                                       │
     [End products: food, wound care, tissue scaffolds] <──── [Formulation & sterile filtration] <──────────────────────────────────┘

Value chain levels

Cross-cutting technologies of the sector:

• Recombinant P4H co-expression: integrating human P4HA1 and P4HB genes into the host genome under strong constitutive (GAP) or inducible (AOX1) promoters, achieving prolyl-hydroxylation levels above 10% critical for maintaining collagen triple-helix thermal stability at human body temperature (37°C).
• Pepsin limited-proteolysis processing: treating crude procollagen extract with pepsin at low pH selectively cleaves the globular N- and C-terminal propeptides that hinder fibril self-assembly, leaving the protease-resistant triple-helical domain intact.
• Tangential-flow-filtration (TFF) concentration: hollow-fiber membrane systems with a 100 kDa cutoff concentrate secreted procollagen 50-100x directly during continuous fermenter offtake, removing low-molecular-weight metabolites and salts without heating the protein.

02US

The United States leads commercialization of recombinant collagen for food, supplement and regenerative-medicine applications, anchored by Geltor’s regulatory breakthrough and emerging animal-free gelatin players.

Geltor’s food-and-beauty-cleared PrimaColl, Jellatech’s animal-free gelatin research backing

• Geltor: its PrimaColl biodesigned collagen polypeptide, engineered to mimic avian Type 21 collagen, became the first biodesigned collagen cleared for both food and beauty applications in October 2025, opening dietary-supplement and beverage use cases for a fully animal-free collagen ingredient.
• Jellatech: develops animal-free gelatin and collagen targeting confectionery and pharmaceutical capsule applications, backed in part by CULT Food Science’s venture arm and included in a Bezos Earth Fund-backed sustainable-protein research center at North Carolina State University.
• Regulatory pathway: Geltor’s food-and-beverage clearance sets a commercial precedent other US precision-fermentation collagen developers are following for GRAS and dietary-supplement market entry.

03CN

China is building regulatory-science infrastructure for recombinant collagen medical devices even as its commercial recombinant-collagen manufacturing base remains concentrated in the cosmetics and injectable-filler segment covered under a separate catalog Industry.

Sichuan University’s medical-device immunological-evaluation research, growing domestic registration pipeline

• Sichuan University National Engineering Research Center for Biomaterials: published a 2026 regulatory-science paper proposing a progressive strategy for pre-market immunological evaluation of recombinant collagen medical devices, co-authored with device manufacturers including Gempharmatech, Jiangsu Trautec Medical Technology and Shanghai LabEx Biotech.
• Domestic registration pipeline: Chinese provincial medical-device regulators have approved a growing number of recombinant-collagen-based wound-care gels and dressings for non-chronic wound and post-procedure skin care, reflecting a broader domestic manufacturing base beyond the aesthetic-injectable segment.
• Market scale context: China’s collagen peptide market alone was estimated to exceed RMB 89 billion in 2026 with China accounting for roughly 38% of the global market, illustrating the scale of downstream demand this recombinant-manufacturing base serves.

04EU

The European Union hosts advanced medical-grade and plant-molecular-farming recombinant collagen manufacturing, serving wound care, ophthalmology and tissue engineering.

HTL Biotechnology’s medical-grade rhCOLIII, CollPlant’s plant-farmed bioink platform, Jellagen’s jellyfish-derived regenerative material

• HTL Biotechnology (France): produces recombinant human Collagen III (rhCOLIII) with 100% sequence identity to native human collagen, manufactured by fermentation from non-animal sources and positioned for medical-grade applications including subcutaneous use.
• CollPlant (Israel/EU manufacturing): its rhCollagen platform produces Type I recombinant human collagen via molecular farming in genetically engineered tobacco, and its Collink.3D bioink supplies 3D bioprinting applications; the company launched its ready-to-print BioFlex bioink in February 2026 and reported Q1 2026 results in May 2026.
• Jellagen (UK): producing jellyfish-derived Collagen Type Zero, formed a strategic partnership with US-based Royal Biologics in early 2026 to commercialize the material for the North American regenerative-medicine market, covering wound care and tissue-engineering applications.

05Leading companies and research institutes

06Tech stack and innovations

The recombinant collagen and gelatin stack combines genetic engineering, fermentation or plant-farming production, and precision downstream processing:

1. Recombinant P4H co-expression cassettes with strong GAP promoters:
   • Human alpha (P4HA1) and beta (P4HB) subunit genes are integrated into the yeast genome under a constitutive GAP promoter, ensuring constant presence of the active P4H tetramer (α2β2) in the endoplasmic reticulum where newly synthesized procollagen chains fold, preventing aggregation and degradation.
2. Tangential-flow-filtration (TFF) concentrators:
   • Since collagen is secreted into the external culture medium, hollow-fiber TFF systems with a 100 kDa molecular-weight cutoff concentrate the procollagen solution 50-100x directly during continuous media offtake from the fermenter, removing low-molecular-weight metabolites and salts.
3. Shelf-programmed lyophilizers:
   • Freeze-drying purified collagen requires precise temperature-gradient control to form a highly porous sponge structure suitable for 3D scaffolds, with programmed profiles from -45°C (primary freezing for controlled ice-crystal size) to +25°C under deep vacuum, preserving the fibrillar structure in the dried product.

07Value chains and production pipelines

Industrial pipeline for recombinant collagen production via yeast fermentation with P4H co-expression (ISO 22000/GMP)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. High-density yeast      │ ───> │ 2. Media clarification     │
│    fermentation (100 m³)       │      │    (centrifuge + TFF)          │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Pepsin processing at    │ <─── │ 3. Ultrafiltration         │
│    pH 2.0 (30°C)               │      │    concentration (100x)        │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Salt precipitation &    │ ───> │ 6. Freeze-drying &         │
│    sterile dialysis            │      │    nitrogen-flushed packaging   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: High-density yeast fermentation

A recombinant Pichia pastoris strain co-expressing human Collagen III (COL3A1) and prolyl-4-hydroxylase (P4HA1/P4HB) genes is cultivated in a 100 m³ fermenter; cells build biomass on glycerol for the first 30 hours at 28°C, pH 5.0, then methanol induction over 72 hours activates the AOX1 promoter, driving P4H-mediated hydroxylation and secretion of procollagen into the culture broth.

Stage 2: Media clarification and yeast-cell removal

The chilled culture broth passes through a continuous disc-stack centrifuge to remove yeast cells as a dense sludge, with the clarified supernatant further polished through depth filters before proceeding to concentration.

Stage 3: Ultrafiltration concentration

The clarified procollagen solution is processed through tangential-flow-filtration cassettes with a 100 kDa cutoff, retaining the roughly 300 kDa triple-helical procollagen while water, salts and low-molecular-weight yeast proteins pass through, concentrating the solution up to 100x.

Stage 4: Pepsin processing at pH 2.0

The concentrated procollagen solution is acidified to pH 2.0 and treated with purified pepsin at a 1:100 ratio to collagen protein for 4 hours at 30°C, selectively cleaving the non-collagenous N- and C-terminal propeptides while the protease-resistant triple helix remains intact.

Stage 5: Salt precipitation and sterile dialysis

The digest is neutralized to pH 7.2, precipitated with sodium chloride to 0.9 M, and the resulting collagen fibers are collected by centrifugation, redissolved in dilute acetic acid, dialyzed against sterile phosphate-buffered saline, and passed through 0.22 μm sterilizing filters in a Class A aseptic zone.

Stage 6: Freeze-drying and nitrogen-flushed packaging

The sterile collagen solution is freeze-dried over a programmed 48-hour cycle into a porous white sponge, milled to powder under sterile conditions, quality-tested for purity, moisture, pH, triple-helix melting temperature and endotoxin content, then packed into sterile vials under nitrogen.